Treatment of patients with rheumatoid arthritis (RA) with non-tumor necrosis factor inhibitor (TNFi) biologic disease-modifying antirheumatic drugs (bDMARDs) may not pose an increased risk for cancer, ...

Please provide your email address to receive an email when new articles are posted on . Conventional synthetic DMARDs did not show a similar protective effect. TNF inhibitors should undergo controlled ...

ROME — Daily baricitinib, an oral Janus kinase (JAK)1/2 inhibitor, produces rapid clinical improvement in the signs and symptoms of rheumatoid arthritis in patients with active disease who have failed ...

Researchers at University of Texas Release New Data on Rheumatoid Arthritis (Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence ...

Weaker immune response against COVID-19 may be attributed to the more targeted immunosuppressive mechanism of biologic DMARDs. Rheumatoid arthritis (RA) patients receiving biologic disease-modifying ...

Worries have persisted that cancer survivors in remission might face increased recurrence risk when treated with biologic drugs for autoimmune disease. This Danish study of rheumatoid arthritis ...

DMARDs are a medication that suppresses the immune system. People may take them to slow disease progression in autoimmune or inflammatory conditions, such as different types of arthritis. Inflammation ...

Researchers evaluated the impact of different treatment modalities in the prevention of psoriatic arthritis (PsA). Biological agents were found more effective than methotrexate in preventing psoriatic ...